RecruitingPhase 3NCT05323149

Tranexamic Acid in Traumatic Brain Injury

The Impact of Early Use of Tranexamic Acid in Traumatic Brain Injury Upon the Inflammatory Response and Outcome


Sponsor

Assiut University

Enrollment

60 participants

Start Date

May 18, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

In this study, our aim is to investigate the role of tranexamic acid for modulating the inflammation in patients with traumatic brain injury (TBI).


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

  • Isolated traumatic brain injury patients (mild or moderate cases)
  • GCS \> 8
  • non penetrating TBI in 8 hours onset
  • Age ≥ 18 years

Exclusion Criteria5

  • Patient in cardiac arrest
  • Patients with coagulopathies
  • Renal failure patients
  • pregnancy
  • Patient refusal to participate

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSaline

Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).

DRUGTranexamic acid

Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).


Locations(1)

Assiut university hospital

Asyut, Assuit, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05323149


Related Trials